January Baron

1.3k total citations
12 papers, 344 citations indexed

About

January Baron is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, January Baron has authored 12 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 7 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in January Baron's work include Multiple Myeloma Research and Treatments (10 papers), Peptidase Inhibition and Analysis (4 papers) and Protein Degradation and Inhibitors (4 papers). January Baron is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Peptidase Inhibition and Analysis (4 papers) and Protein Degradation and Inhibitors (4 papers). January Baron collaborates with scholars based in United States, United Kingdom and Canada. January Baron's co-authors include Trisha Piontek, Ira Gupta, Sagar Lonial, Ashraf Badros, Natalie S. Callander, Ajay K. Nooka, Douglas W. Sborov, Julie Byrne, Joanna Opalinska and Rakesh Popat and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

January Baron

12 papers receiving 337 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
January Baron United States 7 263 213 171 85 32 12 344
Trisha Piontek United States 6 259 1.0× 210 1.0× 166 1.0× 86 1.0× 32 1.0× 12 339
Joanna Opalińska United States 8 245 0.9× 188 0.9× 153 0.9× 90 1.1× 3 0.1× 27 284
Katarina Uttervall Sweden 8 202 0.8× 121 0.6× 122 0.7× 28 0.3× 2 0.1× 25 229
Ilaria Rizzello Italy 5 149 0.6× 96 0.5× 98 0.6× 14 0.2× 10 0.3× 23 183
Anjla Sood United States 7 346 1.3× 181 0.8× 385 2.3× 11 0.1× 4 0.1× 10 476
Daniel Egan United States 8 127 0.5× 123 0.6× 79 0.5× 16 0.2× 3 0.1× 22 212
Rayan Kaedbey Canada 6 140 0.5× 92 0.4× 96 0.6× 26 0.3× 3 0.1× 26 192
Edvan de Queiroz Crusoé Brazil 8 229 0.9× 156 0.7× 233 1.4× 7 0.1× 3 0.1× 41 353
Robin Carson United States 10 204 0.8× 160 0.8× 138 0.8× 28 0.3× 33 258
Joan Bladé Spain 6 416 1.6× 238 1.1× 316 1.8× 35 0.4× 2 0.1× 12 490

Countries citing papers authored by January Baron

Since Specialization
Citations

This map shows the geographic impact of January Baron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by January Baron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites January Baron more than expected).

Fields of papers citing papers by January Baron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by January Baron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by January Baron. The network helps show where January Baron may publish in the future.

Co-authorship network of co-authors of January Baron

This figure shows the co-authorship network connecting the top 25 collaborators of January Baron. A scholar is included among the top collaborators of January Baron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with January Baron. January Baron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Lonial, Sagar, Ajay K. Nooka, Praneetha Thulasi, et al.. (2021). Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer Journal. 11(5). 103–103. 47 indexed citations
2.
3.
Lonial, Sagar, Ajay K. Nooka, Praneetha Thulasi, et al.. (2021). P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21. S149–S150. 1 indexed citations
4.
Farooq, Asim V., Simona Degli Esposti, Rakesh Popat, et al.. (2020). Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmology and Therapy. 9(4). 889–911. 109 indexed citations
5.
Richardson, Paul G., Hans C. Lee, Adam D. Cohen, et al.. (2020). Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer Journal. 10(10). 106–106. 40 indexed citations
6.
Popat, Rakesh, Asim V. Farooq, Praneetha Thulasi, et al.. (2020). Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf). Blood. 136(Supplement 1). 43–44. 2 indexed citations
7.
Nooka, Ajay K., Hans C. Lee, Ashraf Badros, et al.. (2020). Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 136(Supplement 1). 22–23. 1 indexed citations
8.
9.
Cohen, Adam D., Hans C. Lee, Suzanne Trudel, et al.. (2020). MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up. Clinical Lymphoma Myeloma & Leukemia. 20. S304–S305. 4 indexed citations
10.
11.
12.
Griem, Melvin L., et al.. (1981). Combination radiation and chemotherapy for patients with mycosis fungoides. International Journal of Radiation Oncology*Biology*Physics. 7. 45–45. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Trisha Piontek Breakdown of academic impact, for papers by Joanna Opalińska Breakdown of academic impact, for papers by Katarina Uttervall Breakdown of academic impact, for papers by Ilaria Rizzello Breakdown of academic impact, for papers by Anjla Sood Breakdown of academic impact, for papers by Daniel Egan Breakdown of academic impact, for papers by Rayan Kaedbey Breakdown of academic impact, for papers by Edvan de Queiroz Crusoé Breakdown of academic impact, for papers by Robin Carson Breakdown of academic impact, for papers by Joan Bladé
Rankless by CCL
2026